Conclusion of non-exclusive discount agreements in accordance with Section 130 a (8) SGB V with the possibility of concluding at any time in the so-called "OpenHouse process" for various active pharmaceutical ingredients with the earliest possible start of the contract on October 1, 2020.

The specific active pharmaceutical ingredients and the respective start of contracts can be found in the current list of active pharmaceutical ingredients in the project room of the procurement portal dtvp under the heading "Procurement documents".

As of October 1, 2020, contracts will be offered for the following active ingredients:

- abacavir;

- abacavir / dolutegravir / lamivudine;

- abacavir / lamivudine / zidovudine;

- abatacept;

- acetylcysteine RX;

- acetylcysteine non-RX;

- Acetylsalicylic acid only according to Annex 1 AM-RL G-BA products that can be prescribed;

- acitretin;

- adalimumab;

- agomelatine;

- alitretionin;

- ambrisentan;

- amphotericin B;

- Anagrelide except N3 packs from DAR HKP with 0.5 mg strength;

- apomorphine;

- aprepitant;

- Aripiprazole except DAR tablets / orodispersible tablets and oral solutions;

- atazanavir;

- atomoxetine;

- benazepril / HCT;

- bimatoprost;

- biperids;

- bortezomib;

- bosentan;

- brivudine;

- calcipotriol;

- calcium / colecalciferol;

- capsaicin DAR patches;

- chlorine prostheses;

- Cinacalcet;

- cinnarizine / dimenhydrinate;

- Clostridium botulinum;

- clotrimazole;

- colecalciferol non-RX;

- colecalciferol RX;

- colistin;

- cyproterone;

- dabigatran;

- dalteparin;

- Denosumab oncological indication;

- Denosumab orthopedic indication;

- desloratadine;

- desogestrel / ethinyl estradiol;

- dienogest;

- Dienogest / Estradiol;

- dienogest / ethinyl estradiol;

- distigmine;

- dolutegravir;

- Dornase alpha;

- drospirenone / ethinylestradiol;

- dutasteride / tamsulosin;

- ebastine;

- edoxaban;

- efavirenz / emtricitabine / tenofovir;

- Eisen II oral DAR / only prescribable products according to Appendix 1 AM-RL G-BA;

- emtricitabine;

- emtricitabine / tenofovir disoproxil / rilpivirine;

- Enoxaparin 20 mg and 40 mg potency;

- Enoxaparin 60 mg, 80 mg and 100 mg potency;

- erlotinib;

- erythropoietin epoetin;

- estradiol;

- etanercept;

- etravirine;

- febuxostat;

- Fentanyl except DAR matrix patches (transdermal patches);

- Filgrastim;

- flupentixol decanoate;

- fluvastatin;

- follitropin alfa;

- follitropin beta;

- fondaparinux sodium;

- fosamprenavir;

- fosfomycin;

- fulvestrant;

- fusidic acid;

- fusidic acid / betamethasone;

- gefitinib;

- Glatiramer acetate except 40 mg potency;

- goserelin;

- hydrocortisone;

- Hydromorphone DAR solution for injection / infusion;

- hydroxychloroquine;

- hydroxyzine;

- immunoglobulins normal human, intravascular use;

- infliximab;

- Interferon beta 1a Avonex (R);

- irbesartan;

- ivabradine;

- ketorolac;

- Lenograstim;

- leuprorelin;

- Lidocaine DAR patch;

- Lipegfilgrastim;

- loperamide;

- lopinavir / ritonavir;

- Macrogol products that can only be prescribed according to Annex 1 AM-RL G-BA;

- Macrogol exclusively according to Annex 5 AM-RL G-BA medical devices;

- meloxicam;

- meropenem;

- Methocarbamol with the exception of DAR film-coated tablets with 750 mg active ingredient strength;

- midazolam;

- miglustat;

- nadroparin;

- naftidrofuryl;

- natalizumab;

- nifedipine;

- nitrofurantoin;

- octreotide;

- oxycodone / naloxone;

- paliperidone;

- Palonosetron DAR soft capsules;

- pancreatin;

- Paracetamol only products that can be prescribed according to Annex 1 AM-RL G-BA;

- pegfilgrastim;

- peginterferon alpha-2a;

Peginterferon beta-1a;

- pemetrexed;

- perindopril / indapamide;

- piroxicam;

- posaconazole;

- progesterone excluding DAR soft capsules;

- promethazine;

- pyridostigmine;

- rabeprazole;

- raltegravir;

- ritonavir;

- rituximab;

- rotigotine;

- rupatadine;

- salmeterol;

- saquinavir;

- solifenacin;

- somatropin;

- sorafenib;

- sulfasalazine;

- Tacrolimus official ATC: L04AD02;

- Tadalafil Ind. Pulmonary hypertension;

- tapentadol;

- Taurolidine only in accordance with Annex V AM-RL G-BA medical devices that can be prescribed;

- teriparatide;

- Tiotropium bromid Inh. HKP m.Plv.z.Inh;

- Tiotropium bromid Inh.lsg;

- tobramycin;

- tolvaptan;

- Tramadol / Paracetamol;

- trastuzumab;

- travoprost;

- travoprost / timolol;

- triptorelin;

- valsartan / amlodipine;

- Zidovudine.

The contracts all end on September 30, 2022.

The AOK Rhineland / Hamburg announces the conclusion of non-exclusive discount agreements in accordance with § 130 a (8) SGB V with the possibility of concluding at any time in the so-called "OpenHouse process" for various active pharmaceutical ingredients with the earliest possible start of the contract on October 1, 2020.

The specific active pharmaceutical ingredients and the respective, earliest possible start of contracts can be found in the current list of active pharmaceutical ingredients in the project room of the award portal dtvp under the heading "procurement documents".

Providing uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V.

Interested pharmaceutical companies can obtain the participation documents in the project room of the award portal DTVP under the heading "Award documents".

A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents and sends them to the following e-mail box: open-house@rh.aok.de.

Any exchange of documents and documents for the implementation of the OpenHouse process between the companies and the Pharmaceuticals / Pharmacies division of the AOK Rhineland / Hamburg takes place via this e-mail inbox.

A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not conducted.

The earliest contract start date is October 1, 2020. It is possible to conclude or join a discount contract at any time, i.e. even after October 1st, 2020. The contract term ends on September 30, 2022, regardless of the individual contract start.

The list of the contractually active substances is changed at irregular intervals. In this case, all companies verified in the project room in the DTVP award portal will receive an email with information about which active ingredients have been added and when the earliest possible start of the contract is.

Should the AOK Rhineland / Hamburg issue a tender during the contract period

Execute exclusive contracts in the form of the open procedure, the contracts concluded within the scope of this publication are terminated in accordance with the contractual regulations.

This publication is not about awarding a public contract within the meaning of the public procurement coordination directive (2014/24 / EG) or public procurement law. In order to ensure the highest level of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used.

The resulting conceptual requirements, such as the process name "open procedure", are due solely to the use of this notice form and the publication platform. It is not of further importance, in particular submission to procurement regulations, unless they are required for legal reasons connected.